Sirnaomics Ltd
02257
Company Profile
Business description
Sirnaomics Ltd is a therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of drugs for indications with medical needs and large market opportunities. The Group's operations and non-current assets are located at the United States of America and the mainland of the People's Republic of China. All of the company's revenue is derived from the mainland of the People's Republic of China (the PRC). The pipeline includes: STP705, STP707, STP355, STP369, STP705, STP122G, STP125G, and STP144G.
Contact
No.218 Xinghu Street
Unit 415, A4 Building
Suzhou Industrial Park
Suzhou
CHNT: +86 51262956283
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
37
Stocks News & Analysis
stocks
Ask the analyst: Where does GYG stand following its US exit?
All roads lead back home for Guzman Y Gomez.
stocks
Chart of the Week: The long term headwinds facing copper shares
The key factors challenging the bull case for copper demand.
stocks
Australia’s oldest REIT undervalued
This REIT remains undervalued as trophy properties shine through.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,930.90 | 9.20 | 0.10% |
| CAC 40 | 8,474.86 | 137.57 | 1.65% |
| DAX 40 | 25,580.88 | 540.60 | 2.16% |
| Dow JONES (US) | 52,681.57 | 376.33 | 0.72% |
| FTSE 100 | 10,652.87 | 174.53 | 1.67% |
| HKSE | 23,055.03 | 174.01 | 0.76% |
| NASDAQ | 25,829.56 | 210.47 | -0.81% |
| Nikkei 225 | 68,733.15 | 1,741.81 | -2.47% |
| NZX 50 Index | 13,582.19 | 28.31 | -0.21% |
| S&P 500 | 7,470.00 | 13.23 | -0.18% |
| S&P/ASX 200 | 8,724.50 | 13.90 | 0.16% |
| SSE Composite Index | 4,028.90 | 83.54 | -2.03% |